NEUP
Neuphoria Therapeutics Inc.
Medical - Pharmaceuticals
Market Cap$23M
5Y Perf.-97.1%
Build Your Comparison
Side-by-side financial analysisNEUP
ALKS
JPM
Try popular comparisons:
Stock Comparison
NEUP vs ALKS vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
ALKS
Alkermes plc
Biotechnology
Market Cap$7.50B
5Y Perf.+93.4%
JPM
JPMorgan Chase & Co.
Banks - Diversified
Market Cap$908.57B
5Y Perf.+105.4%
NEUP vs ALKS vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  NEUP |  ALKS |  JPM |
|---|---|---|---|
| Industry | Medical - Pharmaceuticals | Biotechnology | Banks - Diversified |
| Market Cap | $23M | $7.50B | $908.57B |
| Revenue (TTM) | $-10M | $1.56B | $280.33B |
| Net Income (TTM) | $-28M | $153M | $57.05B |
| Gross Margin | 100.0% | 65.4% | 60.0% |
| Operating Margin | -7.2% | 12.3% | 25.9% |
| Forward P/E | — | 31.5x | 14.6x |
| Total Debt | $226K | $70M | $942.38B |
| Cash & Equiv. | $22M | $1.12B | $343.34B |
NEUP vs ALKS vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NEUP
ALKS
JPM
| Stock | Dec 21 | Jun 26 | Return |
|---|---|---|---|
| Neuphoria Therapeut… (NEUP) | 100 | 2.9 | -97.1% |
| Alkermes plc (ALKS) | 100 | 193.4 | +93.4% |
| JPMorgan Chase & Co. (JPM) | 100 | 205.4 | +105.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NEUP vs ALKS vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: JPM leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Alkermes plc is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇JPM emerged as the overall leader. Track its performance:
NEUP
Neuphoria Therapeutics Inc.
The Defensive Pick
NEUP is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.38, Low D/E 0.8%, current ratio 3.56x
Best for: sleep-well-at-night
ALKS
Alkermes plc
The Momentum Pick
ALKS is the clearest fit if your priority is momentum and efficiency.
- +53.4% vs NEUP's -34.9%
- 5.4% ROA vs NEUP's -77.5%, ROIC 18.9% vs -13.4%
Best for: momentum and efficiency
JPM
JPMorgan Chase & Co.
The Banking Pick
JPM carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 15 yrs, beta 0.87, yield 1.8%
- Rev growth 3.3%, EPS growth 1.5%
- 481.2% 10Y total return vs ALKS's 7.4%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  JPM | 3.3% NII/revenue growth vs NEUP's -140.1% |
| Value | JPM | Lower P/E (14.6x vs 31.5x) |
| Quality / Margins | JPM | 20.4% margin vs NEUP's -2.4% |
| Stability / Safety | JPM | Beta 0.87 vs NEUP's 1.38 |
| Dividends | JPM | 1.8% yield; 15-year raise streak; the other 2 pay no meaningful dividend |
| Momentum (1Y) |  ALKS | +53.4% vs NEUP's -34.9% |
| Efficiency (ROA) | ALKS | 5.4% ROA vs NEUP's -77.5%, ROIC 18.9% vs -13.4% |
NEUP vs ALKS vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2025
NEUP vs ALKS vs JPM — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLJPMLAGGINGALKS
ALKSAlkermes plc
1leads
NEUPNeuphoria Therapeutic…
1leads
JPMJPMorgan Chase & Co.
3leads
6 Total Categories
CATEGORYLEADERvs NEUPvs ALKSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
JPM3/6
Valuation MetricsMultiples, price ratios, and targets
NEUP4/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ALKS5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
JPM4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
JPM1/1
Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM and NEUP operate at a comparable scale, with $280.3B and -$10M in trailing revenue. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to NEUP's -2.4%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | NEUPNeuphoria Therape… | ALKSAlkermes plc | JPMJPMorgan Chase & … |
|---|---|---|---|
| RevenueTrailing 12 months | -$10M | $1.6B | $280.3B |
| EBITDAEarnings before interest/tax | -$25M | $212M | $81.4B |
| Net IncomeAfter-tax profit | -$28M | $153M | $57.0B |
| Free Cash FlowCash after capex | $59M | $392M | $100.9B |
| Gross MarginGross profit ÷ Revenue | +100.0% | +65.4% | +60.0% |
| Operating MarginEBIT ÷ Revenue | -7.2% | +12.3% | +25.9% |
| Net MarginNet income ÷ Revenue | -2.4% | +9.8% | +20.4% |
| FCF MarginFCF ÷ Revenue | +4.9% | +25.1% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +28.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -101.4% | -4.1% | +16.0% |
JPM leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
NEUP leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
At 16.2x trailing earnings, JPM trades at a 48% valuation discount to ALKS's 31.5x P/E. On an enterprise value basis, JPM's 18.5x EV/EBITDA is more attractive than ALKS's 22.9x.
| Metric | NEUPNeuphoria Therape… | ALKSAlkermes plc | JPMJPMorgan Chase & … |
|---|---|---|---|
| Market CapShares × price | $23M | $7.5B | $908.6B |
| Enterprise ValueMkt cap + debt − cash | $2M | $6.4B | $1.51T |
| Trailing P/EPrice ÷ TTM EPS | -18.74x | 31.46x | 16.22x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 14.60x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.92x |
| EV / EBITDAEnterprise value multiple | — | 22.94x | 18.52x |
| Price / SalesMarket cap ÷ Revenue | 1.49x | 5.08x | 3.25x |
| Price / BookPrice ÷ Book value/share | 0.24x | 4.17x | 2.51x |
| Price / FCFMarket cap ÷ FCF | 0.30x | 15.61x | 9.01x |
NEUP leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
ALKS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-110 for NEUP. NEUP carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), NEUP scores 8/9 vs JPM's 5/9, reflecting strong financial health.
| Metric | NEUPNeuphoria Therape… | ALKSAlkermes plc | JPMJPMorgan Chase & … |
|---|---|---|---|
| ROE (TTM)Return on equity | -109.7% | +8.8% | +15.9% |
| ROA (TTM)Return on assets | -77.5% | +5.4% | +1.3% |
| ROICReturn on invested capital | -13.4% | +18.9% | +4.5% |
| ROCEReturn on capital employed | -3.7% | +14.2% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 7 | 5 |
| Debt / EquityFinancial leverage | 0.01x | 0.04x | 2.60x |
| Net DebtTotal debt minus cash | -$21M | -$1.0B | $599.0B |
| Cash & Equiv.Liquid assets | $22M | $1.1B | $343.3B |
| Total DebtShort + long-term debt | $226,487 | $70M | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | — | 32.30x | 0.74x |
ALKS leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
JPM leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $23,548 today (with dividends reinvested), compared to $244 for NEUP. Over the past 12 months, ALKS leads with a +53.4% total return vs NEUP's -34.9%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.7% vs NEUP's -47.9% — a key indicator of consistent wealth creation.
| Metric | NEUPNeuphoria Therape… | ALKSAlkermes plc | JPMJPMorgan Chase & … |
|---|---|---|---|
| YTD ReturnYear-to-date | +12.8% | +59.2% | +0.8% |
| 1-Year ReturnPast 12 months | -34.9% | +53.4% | +20.9% |
| 3-Year ReturnCumulative with dividends | -85.8% | +38.7% | +138.8% |
| 5-Year ReturnCumulative with dividends | -97.6% | +84.2% | +135.5% |
| 10-Year ReturnCumulative with dividends | -97.6% | +7.4% | +481.2% |
| CAGR (3Y)Annualised 3-year return | -47.9% | +11.5% | +33.7% |
JPM leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ALKS and JPM each lead in 1 of 2 comparable metrics.
Risk & Volatility
JPM is the less volatile stock with a 0.87 beta — it tends to amplify market swings less than NEUP's 1.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 98.3% from its 52-week high vs NEUP's 20.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NEUPNeuphoria Therape… | ALKSAlkermes plc | JPMJPMorgan Chase & … |
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.38x | 0.88x | 0.87x |
| 52-Week HighHighest price in past year | $21.40 | $45.76 | $338.09 |
| 52-Week LowLowest price in past year | $3.65 | $25.17 | $269.72 |
| % of 52W HighCurrent price vs 52-week peak | +20.1% | +98.3% | +96.2% |
| RSI (14)Momentum oscillator 0–100 | 36.3 | 69.5 | 72.1 |
| Avg Volume (50D)Average daily shares traded | 48K | 1.9M | 7.4M |
Evenly matched — ALKS and JPM each lead in 1 of 2 comparable metrics.
Analyst Outlook
JPM leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ALKS as "Buy", JPM as "Buy". Consensus price targets imply 10.0% upside for ALKS (target: $50) vs 4.5% for JPM (target: $340). JPM is the only dividend payer here at 1.83% yield — a key consideration for income-focused portfolios.
| Metric | NEUPNeuphoria Therape… | ALKSAlkermes plc | JPMJPMorgan Chase & … |
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy |
| Price TargetConsensus 12-month target | — | $49.50 | $339.75 |
| # AnalystsCovering analysts | — | 28 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.8% |
| Dividend StreakConsecutive years of raises | — | 0 | 15 |
| Dividend / ShareAnnual DPS | — | — | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% | +3.8% |
JPM leads this category, winning 1 of 1 comparable metric.
Key Takeaway
JPM leads in 3 of 6 categories (Income & Cash Flow, Total Returns). NEUP leads in 1 (Valuation Metrics). 1 tied.
Best OverallJPMorgan Chase & Co. (JPM)Leads 3 of 6 categories
Loading custom metrics...
NEUP vs ALKS vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NEUP or ALKS or JPM a better buy right now?
For growth investors, JPMorgan Chase & Co.
(JPM) is the stronger pick with 3. 3% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 2x trailing P/E (14. 6x forward), making it the more compelling value choice. Analysts rate Alkermes plc (ALKS) a "Buy" — based on 28 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NEUP or ALKS or JPM?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 16. 2x versus Alkermes plc at 31. 5x.
03Which is the better long-term investment — NEUP or ALKS or JPM?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +135. 5%, compared to -97. 6% for Neuphoria Therapeutics Inc. (NEUP). Over 10 years, the gap is even starker: JPM returned +481. 2% versus NEUP's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NEUP or ALKS or JPM?
By beta (market sensitivity over 5 years), JPMorgan Chase & Co.
(JPM) is the lower-risk stock at 0. 87β versus Neuphoria Therapeutics Inc. 's 1. 38β — meaning NEUP is approximately 60% more volatile than JPM relative to the S&P 500. On balance sheet safety, Neuphoria Therapeutics Inc. (NEUP) carries a lower debt/equity ratio of 1% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — NEUP or ALKS or JPM?
By revenue growth (latest reported year), JPMorgan Chase & Co.
(JPM) is pulling ahead at 3. 3% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: JPMorgan Chase & Co. grew EPS 1. 5% year-over-year, compared to -130. 0% for Neuphoria Therapeutics Inc.. Over a 3-year CAGR, NEUP leads at 290. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NEUP or ALKS or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -2. 4% for Neuphoria Therapeutics Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -7. 2% for NEUP. At the gross margin level — before operating expenses — NEUP leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NEUP or ALKS or JPM more undervalued right now?
Analyst consensus price targets imply the most upside for ALKS: 10.
0% to $49. 50.
08Which pays a better dividend — NEUP or ALKS or JPM?
In this comparison, JPM (1.
8% yield) pays a dividend. NEUP, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is NEUP or ALKS or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 1. 8% yield, +481. 2% 10Y return). Both have compounded well over 10 years (JPM: +481. 2%, NEUP: -97. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NEUP and ALKS and JPM?
These companies operate in different sectors (NEUP (Healthcare) and ALKS (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: NEUP is a small-cap quality compounder stock; ALKS is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while NEUP, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.